Pregled bibliografske jedinice broj: 406626
Tamoxifen in trimodal therapy with cytotoxic drugs and hyperthermia in vivo significantly enhance therapeutic efficacy against B16-F10 melanoma
Tamoxifen in trimodal therapy with cytotoxic drugs and hyperthermia in vivo significantly enhance therapeutic efficacy against B16-F10 melanoma // Tumori, 98 (2012), 2; 257-263 doi:10.1700/1088.11939 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 406626 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Tamoxifen in trimodal therapy with cytotoxic drugs and hyperthermia in vivo significantly enhance therapeutic efficacy against B16-F10 melanoma
Autori
Mišir, Krpan, Ana ; Ivanković, Siniša ; Krajina, Zdenko ; Ivanković, Dušica ; Stojković, Ranko
Izvornik
Tumori (0300-8916) 98
(2012), 2;
257-263
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
anticancer drugs ; tamoxifen ; hyperthermia ; combined therapy ; melanoma B16-F10 ; in vivo ; mice
Sažetak
The results of systemic melanoma therapy have been mostly disappointing. Therefore, there is still a great need for strategies that can improve the existent chemotherapy options. The aim of this study was to investigate can the use of antiestrogen tamoxifen (TMX) and heat treatment in the combined therapy with well-known anticancer drugs (cisplatin, cDDP ; dacarbazine, DTIC ; and cyclophosphamide, CTX) enhance their therapeutic efficacy on mouse B16-F10 melanoma in vivo. Drugs were given intraperitoneally 15 min before the application of local hyperthermia (HT) and the tumor growth and mouse survival were followed. The HT alone resulted with a significant delay of tumor growth but the mouse survival was not affected. In bimodal combinations with HT, the all tested antitumor drugs significantly increased both tumor growth delay and mouse survival, with the largest increase recorded in the CTX+HT treatment, followed by the cDDP+HT and DTIC+HT bimodal treatments. In the dosage used, TMX alone did not show any inhibitory effect on B16-F10 melanoma in vivo. However, in the trimodal therapy with particular drug and HT, TXT potentiates the inhibitory effects of the respective bimodal treatments, especially that of CTX and HT. Thus, our results obtained on the mouse melanoma B16-F10 in vivo confirmed the enhanced therapeutic efficacy of the trimodal TXT, HT and anticancer drug combinations in melanoma treatment. Further studies should optimize the heat-drug time scheduling and drug doses that will result with the best possible therapeutic achievement for these trimodal therapy options.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Veterinarska medicina
POVEZANOST RADA
Projekti:
098-0982464-2390 - Novi terapijski modaliteti u liječenju malignih bolesti (Stojković, Ranko, MZOS ) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Klinički bolnički centar Zagreb
Profili:
Zdenko Krajina
(autor)
Siniša Ivanković
(autor)
Ranko Stojković
(autor)
Ana Mišir Krpan
(autor)
Dušica Ivanković
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE